Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor Hypofunction Point of View by Jagannath, Vinita et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on
D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and
Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor
Hypofunction Point of View
Jagannath, Vinita; Brotzakis, Zacharias Faidon; Parrinello, Michele; Walitza, Susanne; Grünblatt, Edna
DOI: https://doi.org/10.3389/fnmol.2017.00342
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-141714
Veröffentlichte Version
 
 
Originally published at:
Jagannath, Vinita; Brotzakis, Zacharias Faidon; Parrinello, Michele; Walitza, Susanne; Grünblatt, Edna
(2017). Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxi-
dase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate
(NMDA) Receptor Hypofunction Point of View. Frontiers in Molecular Neuroscience:10:342.
DOI: https://doi.org/10.3389/fnmol.2017.00342
ORIGINAL RESEARCH
published: 24 October 2017
doi: 10.3389/fnmol.2017.00342
Controversial Effects of D-Amino
Acid Oxidase Activator
(DAOA)/G72 on D-Amino Acid
Oxidase (DAO) Activity in Human
Neuronal, Astrocyte and Kidney Cell
Lines: The N-methyl D-aspartate
(NMDA) Receptor Hypofunction Point
of View
Vinita Jagannath1, Zacharias Faidon Brotzakis2,3, Michele Parrinello2,3,
Susanne Walitza1,4,5 and Edna Grünblatt1,4,5*
1Molecular and Neurobiochemistry Laboratory, Centre for Child and Adolescent Psychiatry Research, Department of Child
and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich,
Switzerland, 2Department of Chemistry and Applied Biosciences, Eidgenössische Technische Hochschule (ETH) Zurich,
Zurich, Switzerland, 3Faculty of Informatics, Institute of Computational Science, Università della Svizzera Italiana (USI),
Lugano, Switzerland, 4Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland, 5Zurich Center
for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
Edited by:
Nicola Maggio,
Sheba Medical Center, Israel
Reviewed by:
Kenji Hashimoto,
Chiba University, Japan
Arturo Ortega,
Center for Research and Advanced
Studies of the National Polytechnic
Institute (CINVESTAV), Mexico
*Correspondence:
Edna Grünblatt
edna.gruenblatt@kjpd.uzh.ch
Received: 03 August 2017
Accepted: 10 October 2017
Published: 24 October 2017
Citation:
Jagannath V, Brotzakis ZF,
Parrinello M, Walitza S and Grünblatt
E (2017) Controversial Effects of
D-Amino Acid Oxidase Activator
(DAOA)/G72 on D-Amino Acid
Oxidase (DAO) Activity in Human
Neuronal, Astrocyte and Kidney Cell
Lines: The N-methyl D-aspartate
(NMDA) Receptor Hypofunction Point
of View.
Front. Mol. Neurosci. 10:342.
doi: 10.3389/fnmol.2017.00342
Dysfunction of D-amino acid oxidase (DAO) and DAO activator (DAOA)/G72 genes have
been linked to neuropsychiatric disorders. The glutamate hypothesis of schizophrenia
has proposed that increased DAO activity leads to decreased D-serine, which
subsequently may lead to N-methyl-D-aspartate (NMDA) receptor hypofunction. It
has been shown that DAOA binds to DAO and increases its activity. However, there
are also studies showing DAOA decreases DAO activity. Thus, the effect of DAOA
on DAO is controversial. We aimed to understand the effect of DAOA on DAO
activity in neuron-like (SH-SY5Y), astrocyte-like (1321N1) and kidney-like (HEK293)
human cell lines. DAO activity was measured based on the release of hydrogen
peroxide and its interaction with Amplex Red reagent. We found that DAOA increases
DAO activity only in HEK293 cells, but has no effect on DAO activity in SH-SY5Y
and 1321N1 cells. This might be because of different signaling pathways, or due
to lower DAO and DAOA expression in SH-SY5Y and 1321N1 cells compared
to HEK293 cells, but also due to different compartmentalization of the proteins.
The lower DAO and DAOA expression in neuron-like SH-SY5Y and astrocyte-like
1321N1 cells might be due to tightly regulated expression, as previously reported
in the human post-mortem brain. Our simulation experiments to demonstrate the
interaction between DAOA and human DAO (hDAO) showed that hDAO holoenzyme
[hDAO with flavine adenine dinucleotide (FAD)] becomes more flexible and misfolded
in the presence of DAOA, whereas DAOA had no effect on hDAO apoprotein
(hDAO without FAD), which indicate that DAOA inactivates hDAO holoenzyme.
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Furthermore, patch-clamp analysis demonstrated no effect of DAOA on NMDA receptor
activity in NR1/NR2A HEK293 cells. In summary, the interaction between DAO and
DAOA seems to be cell type and its biochemical characteristics dependent which still
needs to be elucidated.
Keywords: DAO/DAAO, DAOA/G72, NMDA receptor, SH-SY5Y, 1321N1, HEK293
INTRODUCTION
The human D-amino acid oxidase (DAO/DAAO) gene is located
at chromosome 12q24, and encodes for a ∼39 kDa protein
of 347 amino acids (Verrall et al., 2010). The human DAO
activator (DAOA)/G72 gene is a primate specific gene located
at chromosome 13q33, and encodes for a ∼20 kDa protein
of 153 amino acids (Benzel et al., 2008). Previous studies
have shown evidence for significant association of nucleotide
variations at DAO and DAOA locus with schizophrenia and
bipolar disorder (Detera-Wadleigh and McMahon, 2006; Allen
et al., 2008; Prata et al., 2008; Gatt et al., 2015). Although
the effects of these DAO and DAOA nucleotide variations on
their mRNA and protein expression in schizophrenia is not
yet studied, these genes still remain as candidate genes for
schizophrenia because of their role in the glutamatergic signaling.
DAO is a peroxisomal flavoenzyme. It catalyzes the
oxidation of D-amino acids through concomitant reduction of
flavine adenine dinucleotide (FAD), producing corresponding
imino acid, which is then hydrolyzed to yield ammonia and
corresponding α-keto acid. During FAD reoxidation, hydrogen
peroxide is produced (Verrall et al., 2010). FAD binding is
weaker in human DAO (hDAO) compared to DAO from
other species, which provides hDAO a potential means to
regulate DAO activity (Caldinelli et al., 2009). DAO protein
and enzymatic activity is present mainly in the human kidney,
liver and brain (Sasabe et al., 2014; Uhlén et al., 2015;
Jagannath et al., 2017). In the human brain, its main substrate
is D-serine (Pollegioni et al., 2007; Sacchi et al., 2012).
D-serine serves as a co-agonist at the glycine site of the N-
methyl-D-aspartate (NMDA) receptor. NMDA receptors are
glutamate ionotropic receptors which require both glutamate and
co-agonist (D-serine or glycine) to function normally (Panatier
et al., 2006; Henneberger et al., 2010; Papouin et al., 2012). Thus,
DAO can regulate the function of NMDA receptors via D-serine
breakdown.
The glutamate hypothesis of schizophrenia is based on
the NMDA receptor hypofunction (Stahl, 2007). One possible
explanation for NMDA receptor hypofunction theory proposed
in schizophrenia is increased DAO activity leading to decreased
D-serine which subsequently causes hypofunction of the NMDA
receptors. Chumakov et al. (2002) showed that DAOA binds
to DAO and increases its activity. However, Sacchi et al.
(2008) showed that DAOA binds to DAO and decreases
its activity. Furthermore, Kvajo et al. (2008) showed that
there was no interaction between DAO and DAOA. Thus,
the effect of DAOA on DAO is controversial, and yet to
be elucidated. Previous in vitro studies have shown that
DAOA localizes in mitochondria and causes mitochondrial
dysfunction (Kvajo et al., 2008; Sacchi et al., 2011; Otte
et al., 2014). Thus, the exact function of DAOA is not
yet completely understood. Since the microscopic interactions
between DAO and DAOA may play an additional role in
DAO activation, in silicoMolecular Dynamics (MD) simulations
may contribute in understanding the role of DAOA on DAO
activity. Thus, this approach may contribute to the in vitro
insight into the nature and interactions between these two
proteins. In particular, we performed simulations of different
DAO (apoprotein, holoenzyme) forms with and without DAOA,
and studied the stability of DAO in terms of its flexibility,
thus verifying one of the above DAO and DAOA interaction
hypotheses.
DAO and DAOA proteins are detected in the human brain
with brain region specificity which is tightly regulated (Jagannath
et al., 2017). DAO has been shown to interact with DAOA
in glial cells (Sacchi et al., 2016). However, DAO is not
solely glial, but it has been reported to be also expressed in
neurons (Verrall et al., 2010). In our study, we used neuron-like
SH-SY5Y, astrocyte-like 1321N1 and kidney-like HEK293 cells to
understand the interaction between DAO and DAOA proteins.
We overexpressed DAO and DAOA in these human cell lines
because of the lower endogenous expression of DAO and DAOA
mRNA in these cells (Uhlén et al., 2015; Rouillard et al., 2016).
Since the interaction between DAO and DAOA is still not
clear, we aimed: (1) to understand the effect of DAOA on
DAO activity in different types of human cell lines; and (2) to
understand the effect of DAOA on NMDA receptor activity in
human cell lines.
MATERIALS AND METHODS
Cell Culture
The human embryonic kidney HEK293 cell line (85120602,
Sigma-Aldrich) and human astrocytoma 1321N1 cell line
(86030402, Sigma-Aldrich) were cultured in Dulbecco’s
Modified Eagle Medium (DMEM; 41966029, ThermoFisher
scientific) containing 10% fetal bovine serum (FBS; 10270106,
ThermoFisher scientific), and incubated at 37◦C in a humidified
atmosphere of 5% CO2. The human neuroblastoma SH-SY5Y
cell line (CRL-2266, ATCC) was cultured in a 1:1 mixture of
DMEM and DMEM/F12 (D8437, Sigma-Aldrich) supplemented
with 10% FBS, and incubated at 37◦C in a humidified atmosphere
of 5% CO2.
Transient Transfection
The human LG72 cDNA (GenBank sequence: AY138546) cloned
into the pEGFPN1 vector was a generous gift from the Institute
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of Molecular Psychiatry, University of Bonn, Germany (Otte
et al., 2011), and the pEGFPN1 construct (Takara Clontech)
was used as a control plasmid. The human DAO cDNA
(GenBank sequence: BC029057) cloned into pCMV3-c-Myc
vector (HG13372-CM, Sino Biological) and the pCMV3-c-Myc
vector (CV014, Sino Biological) were used for transfection.
For all experiments except cell viability, HEK293, 1321N1 and
SH-SY5Y cells were seeded into 6-well plates (3335, Corning)
at a density of 2 × 105 cells, 5 × 105 and 1 × 106 cells in
1 mL growth medium, respectively. The cells were allowed to
adhere for 24 h. The cells were transfected with 5 µg of above-
mentioned plasmids using Xfect transfection reagent (631317,
Takara Clontech) according to manufacturer’s guidelines. The
growth medium was exchanged 4 h after transfection. For
all experiments, cells were incubated for 48 h following
transfection.
DAO Activity Assay
In order to evaluate whether DAOA affects DAO activity,
DAO activity was determined based on the estimation of
hydrogen peroxide formation as previously described (Sikka
et al., 2010). The transfected cells were harvested with 0.05%
Trypsin-EDTA (25300054, ThermoFisher Scientific) solution,
transferred to a 15 mL falcon tube and centrifuged for 5 min
at 12,000 × g. The cell pellets were homogenized in 100
µL of cold sodium phosphate buffer (50 mM Na2HPO4,
pH 7.4) with 5 mm stainless steel beads (69989, Qiagen)
using the TissueLyser II (Qiagen). In a 384-well optical-
bottom plate (142761, ThermoFisher Scientific), 10 µL of
homogenate was added to a solution of 100 µM Amplex
red (A36006, ThermoFisher Scientific), 0.25 U/mL horseradish
peroxidase (10108090001, Sigma-Aldrich), 50 mM D-serine
(S4250, Sigma-Aldrich) and with or without 10 µM FAD
(F6625, Sigma-Aldrich) in a total volume of 20 µl of sodium
phosphate buffer. After 1 h of incubation at 37◦C, the
fluorescence was measured with a Mithras2 LB 943 Multimode
Reader (Berthold technologies) using 544 nm excitation (slit
22 nm) and 590 nm emission (slit 20 nm) filters. On each
plate, we included 3 controls namely, a control without cell
homogenate, a control without D-serine and a control inhibiting
DAO activity with a DAO inhibitor, 100 µM 6-methyl-
benzo[d]isoxazol-3-ol (027-640-512, MolPort). The fluorescence
values of cell homogenates were calculated by subtracting
their fluorescence values from fluorescence values of control
without D-serine. As the wells transfected with control plasmids
(pCMV3-c-Myc and pEGFPN1) showed fluorescence similar
to the control without D-serine, fluorescence values of cells
transfected with LG72 and DAO plasmids were used for
analysis.
Cell Viability Assay
We evaluated cell viability to make sure that the results
obtained for DAO activity were not biased by the sensitivity to
different cell lines to transfection. The viability of transfected
cells was determined using CellTiter 96r AQueous One
Solution Cell Proliferation Assay (G3582, Promega) according
to manufacturer’s guidelines. HEK293, 1321N1 and SH-SY5Y
cells were seeded into 96-well plates (83.3925, Sarstedt) at
a density of 2 × 104 cells, 5 × 104 and 1 × 105 cells
in 100 µL growth medium, respectively. They were allowed
to adhere for 24 h and were transfected with 1.2 µg of
plasmids using Xfect transfection reagent (631317, Takara
Clontech) according to manufacturer’s guidelines. The growth
medium was exchanged 4 h after transfection. Each transfection
condition was analyzed in triplicates. The cells were incubated
for 48 h following transfection. Then, 20 µl of CellTiter
96r AQueous One Solution Reagent was added to each
well and incubated at 37◦C for 4 h. The absorbance was
measured at 490 nm using Mithras2 LB 943 Multimode Reader
(Berthold Technologies). The absorbance values were corrected
by subtracting the average absorbance from the control wells with
no cells.
Simulation Setup for hDAO and DAOA
Interactions
In this work, MD simulations were performed. All MD
simulations were carried out using the GROMACS software
(Abraham et al., 2015). In all simulations, the AMBER-14SB
and the TIP3P forcefields (Jorgensen et al., 1983; Maier et al.,
2015) were used for the protein and water, respectively.
The simulated conditions were ambient, at a constant
temperature of 300 K, pressure of 1 atm and concentration
(NPT ensemble). The simulated systems were: hDAO
without FAD in water, FAD/hDAO complex in water,
FAD/hDAO/DAOA complex in water and hDAO/DAOA
complex in water.
hDAO Without FAD (apoprotein)
The hDAO monomer structure was extracted from the dimer
protein data bank (PDB) structure of hDAO (PDB: 2E48), and
the FAD ligand was removed.
FAD/hDAO (holoenzyme) Complex
The structure of this complex was obtained by extracting
the hDAO monomer structure from the dimer PDB structure
of hDAO while retaining the FAD ligand. The topology of
the complex was obtained using the AMBER tools and the
AMBER-14SB forcefield, after having created the FAD topology.
The FAD topology was obtained using the gaff forcefield,
followed by a geometry optimization using Gaussian package
and the B3LYP/6-31G, constructing the electrostatic potential
surface and assigning charges to atoms using RESP (Bayly et al.,
1993).
FAD/hDAO/DAOA Complex
The structure of this complex was obtained by using the
patchdock docking server (Schneidman-Duhovny et al., 2005),
and adding constraints on the dimer interface so that DAOA
residues 138, 139, 140, 141, 142, 143, 144, 145, 146, 147,
148, 149, 150, 151, 152, 153 were within 0.4 nm of any
amino acids within 1 nm of hDAO amino acids 37, 138, 163,
185, 188, 191, 193, 194, 195, 196. These contacts have been
found to occur in the hDAO-DAOA complex (Chang et al.,
2014). As mentioned earlier, building the FAD topology and
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using AMBER tools to combine the topology of FAD, hDAO
and G72 protein, the final complexes topology was obtained.
Simulations were performed using the structure of the best
binding pose.
hDAO/DAOA Complex
The procedure for constructing the structure of this complex was
the same as the above ones, except the topology of the complex
was obtained by using the AMBER tools for complex’s structure.
DAOA Protein
Since there was no available crystal structure for the
human DAOA protein, we obtained its structure by using
homology modeling of the protein sequence with accession
number AAN08432. The homology modeling was performed
using the I-TAISER server (Yang and Zhang, 2015). The
best predicted homolog structure was used as the DAOA
protein.
NMDA Receptor Currents Using
Whole-Cell Patch Clamp Recording
HEK293 cells stably expressing NMDA receptor subunits
NR1 and NR2A (NR1/NR2A HEK293 cells; B’SYS, Switzerland)
were used. They were cultured in DMEM/F12 (D8437,
Sigma-Aldrich) supplemented with 10% FBS (RNBF7902,
ThermoFisher scientific), 1% penicillin/streptomycin (10378016,
ThermoFisher scientific), 100 µg/mL hygromycin (10687010,
ThermoFisher scientific), 15 µg/mL blasticidin (A1113903,
ThermoFisher scientific), 1 µg/mL puromycin (A1113803,
ThermoFisher scientific) and incubated at 37◦C in a humidified
atmosphere of 5% CO2. The cells (2× 105 cells/well) were seeded
onto Poly-L-Lysine (P4832, Sigma-Aldrich) coated coverslips
placed in 6-well plates (92412, TPP) and were allowed to adhere
for 24 h. The cells were transfected with 5 µg of LG72 and
control pEGFPN1 plasmids using Xfect transfection reagent
according to manufacturer’s guidelines. The growth medium
was exchanged 4 h after transfection. Expression of NR1 and
NR2A subunits in the cells were induced 24 h after transfection
using 2.5 µg/mL tetracycline (T7660, Sigma-Aldrich) in the
presence of 50 µM AP5 (ab120003, abcam). The whole-cell
patch clamp recording was performed 48 h after transfection
at room temperature using Amplifier EPC-10 and Preamplifier
EPC-10 (both, HEKA Electronics). For recording, the coverslips
with transfected or non-transfected cells were placed in a
35-mm culture dish containing 2 mL of standard bath solution
(137 mM sodium chloride, 4 mM potassium chloride, 1.8 mM
calcium chloride, 1 mM magnesium chloride, 10 mM HEPES,
10 mM D-Glucose, pH 7.4 adjusted with sodium hydroxide).
The transfected cells were identified visually by green florescent
protein (GFP) fluorescence signal using inverted microscope
IM (Zeiss). The patch pipettes were filled with pipette solution
(130 mM potassium chloride, 1 mMmagnesium chloride, 5 mM
magnesium-ATP, 10 mMHEPES, 5 mM EGTA, pH 7.2 adjusted
with potassium hydroxide). After formation of Gigaohm seal
between the patch pipettes and single cell (pipette resistance
range: 2.5 MΩ to 6.0 MΩ; seal resistance range: >1 GΩ),
the cell membrane across the pipette tip was ruptured to
ensure electrical access to the cell interior (whole-cell patch
configuration). In case of poor seal quality, the process of seal
formation was repeated with a different cell and a new pipette.
As soon as a stable seal was established, magnesium-free bath
solution (137 mM sodium chloride, 4 mM potassium chloride,
2.8 mM calcium chloride, 10 mM HEPES, 10 mM D-Glucose,
0.02% Cremophor, pH 7.4 adjusted with sodium hydroxide)
was perfused and NMDA inward currents were measured upon
application of submaximal concentrations of NMDA (100 µM;
M3262, Sigma-Aldrich)/Glycine (5 µM; 410225, Sigma-Aldrich)
to patch-clamped cells for 4 s. If the current was too unstable
for measurement, another cell was recorded. During the entire
experiment, the membrane potential of the cell was clamped
at −80 mV. We used only data from cells treated with the
complete application protocol for analysis. At least five cells
were recorded per condition and three independent experiments
were performed. Data was acquired using PatchMaster (HEKA
Electronics, version v2x73_2) software and analyzed using
Microsoft Excel 2003 software. The NMDA peak current density
was calculated by dividing means of peak current amplitudes
(pA) from at least 5 cells by cell capacitance (pF). The NMDA
mean current density was calculated by dividing means of steady
state current amplitudes (pA) from at least five cells by cell
capacitance (pF).
Statistical Analysis
The results presented in this study are from at least three
independent experiments. IBMr SPSSr Statistics (version 23)
software was used for statistical analysis. Shapiro-Wilk test with
Lilliefors significance correction was used to assess the normality
of the distribution of NMDA receptor current, DAO activity
and cell viability data. As the NMDA receptor current data
was normally distributed, we used one-way analysis of variance
(ANOVA) followed by post hoc Bonferroni test to analyze the
difference between the groups, and p < 0.05 was considered
statistically significant. As the DAO activity and cell viability
data was also normally distributed, we used independent-
samples t-test to analyze the difference between two groups, and
p< 0.05 was considered statistically significant. GraphPad Prism
software (version 6.01) was used to plot the graphs.
RESULTS
DAO Activity and Cell Viability in SH-SY5Y
Cells
To understand the effect of DAOA on DAO activity, SH-SY5Y
cells were transfected with either DAO plasmid alone or
both DAO and G72 plasmids. To achieve DAO-activity
signal in SH-SY5Y cells, the addition of 10 µM FAD
was necessary. There were no significant differences in
DAO activity between the two transfection conditions,
namely DAO and G72+DAO (Figure 1A). In order to
verify that the non-significant differences in DAO activity
between single (DAO) and double transfection (G72+DAO)
conditions is not due to cell death, we performed cell
viability assay. There were no significant differences in
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FIGURE 1 | D-amino acid oxidase (DAO) activity and cell viability in SH-SY5Y cells. (A) DAO activity with the addition of 10 µM flavine adenine dinucleotide (FAD)
across two transfection conditions: DAO and G72+DAO. (B) Cell viability across two transfection conditions: DAO and G72+DAO. Data is presented as bar graphs
with mean ± SEM. Differences between the two transfection conditions was assessed by the independent-samples t-test.
FIGURE 2 | DAO activity and cell viability in 1321N1 cells. (A) DAO activity without the addition of 10 µM FAD across two transfection conditions: DAO and
G72+DAO. (B) DAO activity with the addition of 10 µM FAD across two transfection conditions: DAO and G72+DAO. (C) Cell viability across two transfection
conditions: DAO and G72+DAO. Data is presented as bar graphs with mean ± SEM. Differences between the two transfection conditions was assessed by the
independent-samples t-test.
cell viability between the two transfection conditions
(Figure 1B).
DAO Activity and Cell Viability in
1321N1 Cells
To verify the results obtained in SH-SY5Y neuroblastoma
cells with neuron-like phenotype, we retested effects of DAOA
on DAO activity in the human 1321N1 cells which have
an astrocyte-like phenotype. Again, we single and double
transfected 1321N1 cells with DAO plasmid and both DAO
and G72 plasmids, respectively. In contrast to SH-SY5Y cells,
DAO activity assay in 1321N1 cells worked both with and
without addition of 10 µM FAD. We did not find any
significant differences in DAO activity without (Figure 2A)
and with (Figure 2B) addition of 10 µM FAD between the
two transfection conditions as well as no significant differences
in cell viability between the two transfection conditions
(Figure 2C).
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FIGURE 3 | DAO activity and cell viability in HEK293 cells. (A) DAO activity without the addition of 10 µM FAD across two transfection conditions: DAO and
G72+DAO. (B) DAO activity with the addition of 10 µM FAD across two transfection conditions: DAO and G72+DAO. (C) Cell viability across two transfection
conditions: DAO and G72+DAO. Data is presented as bar graphs with mean ± SEM. Differences between the two transfection conditions was assessed by the
independent-samples t-test (∗p < 0.05).
DAO Activity and Cell Viability in
HEK293 Cells
To test the tissue related specificity of the results obtained
in neuron-glia like cell lines, we determined the effect of
DAOA on DAO activity also in human HEK293 cells with
kidney epithelium-like phenotype. HEK293 cells were single
and double transfected with DAO plasmid and with both DAO
and G72 plasmids, respectively to understand the effect of
DAOA on DAO activity. Similar to 1321N1 cells, DAO activity
assay in HEK293 cells worked with and without addition of
10 µM FAD. In contrast to SH-SY5Y and 1321N1 cells, DAO
activity without (t = 3.024, df = 10, p = 0.013; Figure 3A)
and with (t = 5.305, df = 10, p = 0.0003; Figure 3B)
addition of 10 µM FAD was significantly increased in double
transfected HEK293 cells (G72+DAO) compared to the single
transfected (DAO) HEK293 cells. The cell viability assay was
performed to confirm that the differences in DAO activity are
not due to cell death. There were no significant differences
in cell viability between the two transfection conditions
(Figure 3C).
Although DAO protein was detected at the expected size
of 40 kDa in pEGFPN1+pCMV3-c-Myc and pCMV3-c-Myc
transfection conditions in all three cell lines (data not shown),
we could not detect DAO activity signal in these transfection
conditions which might be because the endogenous DAO
enzyme is in FAD unbound inactive state.
In Silico Interactions between hDAO and
DAOA
In order to understand the effect of DAOA protein on
the holoenzyme (FAD/hDAO) and apoprotein (hDAO
without FAD) form of the hDAO, the fluctuations of the
Cα atoms of each amino acid were determined. We found
that there was a slight decrease in FAD/hDAO complex
flexibility compared to hDAO without FAD (Figure 4A).
Our simulations show that upon FAD/hDAO/DAOA
complex formation, FAD/hDAO become much more flexible
(Figure 4B) and misfolded (Figure 4C) than FAD/hDAO
complex without DAOA. Contrarily, the apoprotein form
of the hDAO when in complex with DAOA, shows much
less flexibility (Figure 4B), and retains its folded structure
(Figure 4D).
NMDA Receptor Currents in NR1/NR2A
HEK293 Cells
To understand the effect of DAOA on NMDA receptor
activity, NR1/NR2A HEK293 cells were transfected with
G72 plasmid. There were no significant differences in
mean NMDA receptor current (Supplementary Figure
S1A) or in peak NMDA receptor current (Supplementary
Figure S1B) between all three conditions namely,
G72 transfected, pEGFPN1 plasmid transfected and non-
transfected.
DAO and DAOA mRNA Expression in
Transfected SH-SY5Y, 1321N1 and
HEK293 Cells
In order to verify and compare the expression of endogenous
and overexpressed DAO and DAOA mRNA in transfected
SH-SY5Y, 1321N1 and HEK293 cells, we measured the
DAO and DAOA mRNA levels using qRT-PCR. We found
that there were no significant differences in DAO mRNA
levels between the double transfection (G72+DAO) and
single transfection (DAO) conditions in SH-SY5Y and
1321N1 cells, but a significantly lower endogenous DAO
mRNA levels in pEGFPN1+pCMV3-c-Myc and pCMV3-
c-Myc transfected compared to the G72+DAO and DAO
transfected SH-SY5Y (F = 74.91, df = 3, p < 0.0001) and
1321N1 cells (F = 135.98, df = 3, p < 0.0001; Figure 5A).
There was a significant decrease in DAO mRNA levels
in double transfected (G72+DAO) compared to the single
transfected (DAO) HEK293 cells (Bonferroni test p = 0.001),
and endogenous DAO mRNA levels were significantly lower
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FIGURE 4 | Fluctuations and 3D conformations of human DAO (hDAO) holoenzyme and apoprotein complex with DAO activator (DAOA). Room mean square
fluctuations of the Cα atom per amino acid (#AA) of (A) the hDAO without FAD (red), and the FAD/hDAO complex (green), and (B) the hDAO/DAOA complex (red)
and FAD/hDAO/DAOA complex (green). Note that the amino acid index 0-340 corresponds to the hDAO Cα atoms, whereas the index 341-494 corresponds to the
Cα atoms of DAOA amino acids. 3D conformations taken from Molecular Dynamics (MD) simulation of holoenzyme FAD/hDAO/DAOA complex (C) and apoprotein
hDAO/DAOA complex (D) with hDAO in green color and DAOA in blue color.
in pEGFPN1+pCMV3-c-Myc and pCMV3-c-Myc transfected
HEK293 cells compared to G72+DAO and DAO transfected
HEK293 cells (F = 182.58, df = 3, p < 0.0001; Figure 5A).
We found that the endogenous DAOA mRNA levels were
significantly lower in DAO, pEGFPN1+pCMV3-c-Myc,
pCMV3-c-Myc transfected than G72+DAO transfected
SH-SY5Y (F = 3656.23, df = 3, p < 0.0001), 1321N1 (F = 112.39,
df = 3, p < 0.0001) and HEK293 cells (F = 858.86, df = 3,
p < 0.0001; Figure 5B). There were significant differences
in DAO mRNA levels between the three cell lines in
G72+DAO transfection condition (F = 213.76, df = 2,
p < 0.0001; Figure 5C), and DAO mRNA levels were the
highest in HEK293 cells compared to the 1321N1 and
SH-SY5Y cells in DAO transfection condition (F = 222.68,
df = 2, p < 0.0001; Figure 5D). We found that there were
significant differences in DAOA mRNA levels between the
three cell lines both in G72+DAO (F = 164.83, df = 2,
p < 0.0001; Figure 5E) and DAO (F = 56.35, df = 2,
p < 0.0001; Figure 5F) transfection conditions. DAOA
mRNA levels were the highest in HEK293 cells followed by
intermediate levels in 1321N1 cells and low levels in SH-SY5Y
cells.
DAO and DAOA Protein Expression in
Transfected SH-SY5Y, 1321N1, and
HEK293 Cells
To verify and compare the overexpression of DAO and DAOA
proteins in transfected SH-SY5Y, 1321N1 and HEK293 cells, we
determined DAO and DAOA proteins using western blot. DAO
protein was detected in all three cell lines at the expected size
of 40 kDa in G72+DAO (Figure 6A) and DAO (Figure 6E)
transfection conditions. DAO protein levels were the highest
in 1321N1 cells compared to HEK293 and SH-SY5Y cells in
G72+DAO (Figure 6B) and DAO (Figure 6F) transfection
conditions. We detected c-Myc-DAO fusion protein in all three
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FIGURE 5 | DAO and DAOA mRNA levels in SH-SY5Y, 1321N1 and HEK293 cells across different transfection conditions. DAO (A) and DAOA (B) mRNA levels
across four transfection conditions: DAO, G72+DAO, pCMV3-c-Myc and pEGFPN1+ pCMV3-c-Myc in all three cell lines. DAO mRNA levels in two transfection
conditions: G72+DAO (C) and DAO (D). DAOA mRNA levels in two transfection conditions: G72+DAO (E) and DAO (F). Data is presented as bar graphs with
mean ± SEM. Differences in DAO and DAOA mRNA levels between four transfection conditions, and also between the three cell lines was assessed by one-way
analysis of variance (ANOVA) followed by post hoc Bonferroni test (∗p < 0.05).
cell lines at the expected size of 41 kDa in G72+DAO (Figure 6C)
and DAO (Figure 6G) transfection conditions. HEK293 cells
had highest c-Myc-DAO fusion protein levels compared to
1321N1 and SH-SY5Y cells in G72+DAO (Figure 6D) and DAO
(Figure 6H) transfection conditions. DAOAprotein was detected
in all three cell lines at the expected size of 18 kDa in G72+DAO
(Figure 6I) and DAO (Figure 6M) transfection conditions.
DAOA protein levels were the highest in HEK293 cells compared
to 1321N1 and SH-SY5Y cells in G72+DAO (Figure 6J) and
DAO (Figure 6N) transfection conditions. GFP-DAOA fusion
protein was detected in all three cell lines at the expected
size of 45 kDa in the double transfection with G72+DAO
(Figure 6K), but not in the single transfection with DAO
(Figures 6O,P). GFP-DAOA fusion protein levels were the
highest in HEK293 cells compared to 1321N1 and SH-SY5Y cells
in G72+DAO (Figure 6L) transfection condition.
DISCUSSION
DAO and DAOA genes are alleged to be involved in
pathophysiology of neuropsychiatric disorders such as
schizophrenia and bipolar disorder (Detera-Wadleigh and
McMahon, 2006; Allen et al., 2008; Prata et al., 2008; Gatt et al.,
2015), but the interactions between these genes remains unclear
to date. There are several lines of evidence in humans suggesting
NMDA receptor hypofunction in the pathophysiology of
schizophrenia. Healthy controls manifested primary symptoms
of schizophrenia on administration of NMDA receptor
antagonists such as phencyclidine and ketamine (Anis et al.,
1983; Krystal et al., 1994). Patients with NMDA receptor specific
antibodies were reported to be associated with severe psychosis
(Dalmau et al., 2008). A study revealed reduced expression
of obligatory NMDA receptor subunit NR1 in post-mortem
brains of schizophrenia patients (Weickert et al., 2013), and
reduced D-serine in cerebrospinal fluid of schizophrenia patients
(Hashimoto et al., 2005). Studies have also shown increased
DAO activity in brains of schizophrenia patients compared to
the healthy controls (Kapoor et al., 2006; Burnet et al., 2008;
Madeira et al., 2008). There is only one published study using
single-photon emission computed tomography (SPECT) with
NMDA receptor tracer [123I]CNS-1261 which showed lower
NMDA receptor binding in left hippocampus of schizophrenia
patients compared to healthy controls (Pilowsky et al., 2006),
however this finding awaits confirmation. Although, the
aforementioned studies provide evidence for NMDA receptor
hypofunction in schizophrenia, it is still not clear what NMDA
receptor hypofunction means at the molecular level. At present
there are no drugs on the market to treat the negative symptoms
and cognitive deficits of schizophrenia, and clinical trials with
DAO inhibitors or D-serine have not shown a conclusive or
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FIGURE 6 | DAO and DAOA protein levels in SH-SY5Y, 1321N1 and HEK293 cells. Representative western blot images for DAO protein expression levels in three
cell lines across two transfection conditions: G72+DAO (A) and DAO (E), and DAO protein detected at an expected size of 40 kDa. DAO protein levels (arbitrary
units) in three cells lines across two transfection conditions: G72+DAO (B) and DAO (F). Representative western blot images for c-Myc-DAO fusion protein
expression levels in three cell lines across two transfection conditions: G72+DAO (C) and DAO (G), and c-Myc-DAO fusion protein detected at an expected size of
41 kDa. c-Myc-DAO protein levels (arbitrary units) in three cells lines across two transfection conditions: G72+DAO (D) and DAO (H). Representative western blot
images for DAOA protein expression levels in three cell lines across two transfection conditions: G72+DAO (I) and DAO (M), and DAOA protein detected at an
expected size of 18 kDa. DAOA protein levels (arbitrary units) in three cells lines across two transfection conditions: G72+DAO (J) and DAO (N). Representative
western blot images for green florescent protein (GFP)-DAOA fusion protein expression levels in three cell lines across two transfection conditions: G72+DAO (K) and
DAO (O), and GFP-DAOA fusion protein detected at an expected size of 45 kDa. GFP-DAOA protein levels (arbitrary units) in three cells lines across two transfection
conditions: G72+DAO (L) and DAO (P).
strong effect in schizophrenia (Smith et al., 2010). Thus, there
is an urgent need for new drugs for the treatment of negative
symptoms and cognitive deficits of schizophrenia, which might
be achieved by understanding the interaction between DAO
and DAOA, and their subsequent effect on NMDA receptors.
In this study, we aimed to understand the interaction between
DAO and DAOA by determining the effect of DAOA on DAO
and NMDA receptor activity in different types of human cell
lines.
We chose three human cell lines namely, neuron-like
SH-SY5Y, astrocyte-like 1321N1 cells, and kidney-like
HEK293 cells to verify and compare the effects of DAOA
on DAO activity. We found that DAOA increases the activity
of DAO only in HEK293 cells, but not in the SH-SY5Y and
1321N1 cells. One possible reason for this result might be because
of different signaling pathways in kidney-like HEK293 cells vs.
neuron-like SH-SY5Y and astrocyte-like 1321N1 cells. Moreover,
our previous post-mortem study (Jagannath et al., 2017) showed
that there is a tight transcriptional regulation in DAO and
DAOA expression in the human brain during development and
aging, which might also be the reason that we found no effect
of DAOA on DAO activity in the neuron-like SH-SY5Y and
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astrocyte-like 1321N1 cells. Chumakov et al. (2002) showed
that increasing concentrations of recombinant human DAOA
protein causes porcine DAO activation. In the current study,
we found that HEK293 cells overexpressed DAOA mRNA
significantly more than in SH-SY5Y and 1321N1 cells, which
might explain why DAO activity increased only in HEK293 cells
when co-transfected with DAOA. A study conducted using
recombinant hDAO and DAOA proteins isolated from E.coli
found that DAOA increases DAO activity (Chang et al., 2014),
but a recent study using recombinant hDAO and DAOA
proteins isolated from E.coli found that DAOA decreases DAO
activity (Birolo et al., 2016). Moreover, another study found that
DAOA even decreases DAO activity in human glioblastoma
U87 cell line (Sacchi et al., 2008). However, following the last
result, a study conducted in human glioblastoma U251 cell line,
reported that DAOA has no effect on DAO activity (Kvajo et al.,
2008). All these studies performed the DAO activity assay based
on the detection of hydrogen peroxide released from oxidation
of D-amino acids by the DAO enzyme. The differences in results
found in these studies might be because of substrate, cell lines
and enzymatic reaction temperature used (see summary in
Table 1). Chumakov et al. (2002) used recombinant human
DAOA but recombinant porcine DAO to perform DAO activity
assay with D-serine as substrate and the enzymatic reaction
was performed at 30◦C. However, two independent research
groups used D-alanine as substrate and the assay was performed
at 25◦C (Chang et al., 2014; Birolo et al., 2016). Furthermore,
another two groups conducted the DAO activity assay at room
temperature, but Kvajo et al. (2008) used D-proline as substrate,
while Sacchi et al. (2008) used D-serine as substrate. In our
study, we used D-serine as substrate and performed the assay at
37◦C, which corresponds to the human body temperature. The
DAO activity assay conducted with D-proline as substrate (Kvajo
et al., 2008) can be biased because D-proline is also a substrate of
human D-aspartate oxidase (Katane et al., 2015). A study found
that DAO shows lower catalytic efficiency and substrate affinity
on the physiological substrate D-serine compared to D-alanine
(Molla et al., 2006b), which might explain the discrepancies
found between studies using these substrates. We found that
DAO activity assay worked in 1321N1 and HEK293 cells even
without the addition of 10 µM FAD, which might be because
of endogenous production of FAD by these cells. Indeed, FAD
co-factor binding was reported to be essential for the DAO
enzyme activity (Molla et al., 2006b). Nevertheless, we found that
addition of 10 µM FAD had no effect on the results obtained
comparing to those obtained without the addition of 10 µM
FAD in these two cell lines. In studies using recombinant DAO
and DAOA proteins, two of the studies, which did not use FAD
in DAO activity assay, found DAOA to be a DAO activator
(Chumakov et al., 2002; Chang et al., 2014). However, a recent
study with human recombinant DAO and DAOA proteins,
where they added FAD in DAO activity assay found DAOA to
be a DAO inhibitor (Birolo et al., 2016). Thus, additional studies
in a more realistic conditions i.e., human induced pluripotent
stem cells (hiPSC) derived neurons and glia using gene editing
tools will be required to conclusively determine whether DAOA
is a DAO activator or inhibitor.
In our simulation experiments, we found that there
is a slight decrease in FAD/hDAO (holoenzyme) complex
flexibility compared to the hDAO without FAD (apoprotein)
which indicates that the hDAO holoenzyme is more stable
than the hDAO apoprotein. This result coincides with the
previous spectroscopic evidence of hDAO holoenzyme having
slightly higher melting temperature than the hDAO apoprotein
(Caldinelli et al., 2009; Sacchi et al., 2012). Previous studies
based on spectroscopy and proteolysis experiments have shown
that DAOA changes the tertiary structure of FAD/hDAO and
leads to decrease in hDAO holoenzyme form (Caldinelli et al.,
2010), which is in line with our simulations that showed
DAOA makes FAD/hDAO more flexible (i.e., less stable) and
misfolded. However, our simulations showed that DAOA had no
effect on hDAO apoprotein structure which corroborates with
previous proteolysis experiments that showed hDAO apoprotein
structure is not affected by DAOA (Caldinelli et al., 2010). The
difference in flexibility of hDAO apoprotein and holoenzyme
in complex with DAOA can be explained by the different
binding positions of DAOA. DAOA binds to hDAO holoenzyme
much closer to the FAD binding pocket, which causes an
increase in the complex’s fluctuations (i.e., less stable), compared
to the hDAO apoprotein where DAOA binds slightly farther
away from the FAD binding pocket. Thus, our simulations
indicate that DAOA inactivates hDAO holoenzyme and not the
hDAO apoprotein. However, we did not observe the similar
inactivating effect of DAOA on DAO activity in our cell lines
which might be due to the fact that in our simulations we
used only hDAO and DAOA proteins in an artificial system.
Moreover, as indicated in our previous postmortem study
(Jagannath et al., 2017), the tight regulation of DAO and
DAOA in the human brain compared to the periphery might
be an additional reason for the in vitro differences found in
neuron-like and astrocyte-like cells compared to the kidney-like
cells.
Accordingly, going one-step forward, we tested whether
DAOA overexpression modulates NMDA receptor activity using
induced NR1/NR2A HEK293 cells. In this study, we did not find
an effect of DAOA on NMDA receptor currents in NR1/NR2A
HEK293 cell line, despite our results showing DAOA increases
DAO activity in HEK293 cells. This might be because of several
reasons namely; the endogenous DAO (binding partner of
DAOA) in NR1/NR2A HEK293 cell line is not in an active
form leading to no effect on D-serine, unavailability of D-serine
transporters in these NR1/NR2A HEK293 cells to transport
the D-serine extracellularly for its action on NMDA receptors,
and the DAOA transfected NR1/NR2A HEK293 cell line is an
artificial model system which doesn’t recapitulate the human
tripartite synapse and the complex signaling pathways of human
neurons and glia. A study conducted in primary cultures
from rat hippocampus using whole cell patch clamp technique
showed that DAO inhibitors lead to increase in NMDA receptor
mediated currents (Strick et al., 2011). To our knowledge, there
are no articles showing the effect of DAOA on NMDA receptor
currents in vitro. Thus, future experiments must be conducted,
probably also in a more complex cellular system, to understand
the effect of DAOA on NMDA receptors.
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In summary, we found that DAOA increases DAO activity
only in kidney-like HEK293, but not in neuron-like SH-SY5Y
and astrocyte-like 1321N1 cells. We also found no effect
of DAOA on NMDA receptor currents in NR1/NR2A
HEK293 cells. As our study was performed using human
cell lines, in order to confirm the tight regulation of DAO and
DAOA assumed in the human central nervous system (CNS),
modeling the interactions between DAO and DAOA proteins
in schizophrenia patient specific neuroglial culture i.e., hiPSC
derived neurons and glia co-cultures and comparing them to
healthy control derived neuroglial cultures might further help in
settling the debate of DAOA effect on DAO and NMDA receptor
activity.
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